CEPI

Solving COVID and Climate: 'Innovation Without Borders'

Retrieved on: 
Tuesday, September 14, 2021
Knowledge, Science, Discovery, Technology, LEAP, WIPO, CEPI, World Trade Organization, Public sector, Patent, WHO, UNEP, CAP, Collective action, API, Global South, Policy, Solution, Community Access Program, University, Report, Observation, GLOBE, Leadership, Pharmaceutical industry

We need to jump-start inclusive and deliberate problem-solving that engages all the world's people and institutions in evidence-driven partnerships.

Key Points: 
  • We need to jump-start inclusive and deliberate problem-solving that engages all the world's people and institutions in evidence-driven partnerships.
  • Today, The Lens announces the launch of the Collective Action Project - a multi-year initiative to enable open innovation knowledge for solving problems together.
  • This observation shifts the narrative around patents towards its original purpose of putting knowledge in the public domain to stimulate innovation.
  • View the full Press Release , read more about the Collective Action Project or watch the accompanying launch video .

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

Retrieved on: 
Thursday, September 9, 2021

The event will highlight the GRANITE (individualized neoantigen immunotherapy) Phase 1/2 data in advanced solid tumors which is being presented during a mini- oral presentation at ESMO 2021, in addition to data from the SLATE v1 shared neoantigen immunotherapy program in KRAS mutant advanced solid tumors.

Key Points: 
  • The event will highlight the GRANITE (individualized neoantigen immunotherapy) Phase 1/2 data in advanced solid tumors which is being presented during a mini- oral presentation at ESMO 2021, in addition to data from the SLATE v1 shared neoantigen immunotherapy program in KRAS mutant advanced solid tumors.
  • The call and accompanying slides will be webcast live on the Events page under the Investors & Media section of the companys website at www.gritstone.com .
  • Daniel Catenacci, M.D., is an associate professor of medicine and director of the gastrointestinal oncology program at the University of Chicago.
  • Additionally, Dr. Catenacci designs and executes novel clinical trials to implement treatment strategies based on these laboratory and clinical discoveries.

Gritstone Announces Presentations at Two Investor Conferences in September

Retrieved on: 
Tuesday, September 7, 2021

EMERYVILLE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will present webcasted company overviews at two upcoming investor conferences in September.

Key Points: 
  • EMERYVILLE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will present webcasted company overviews at two upcoming investor conferences in September.
  • A live webcast of the presentations will be accessible via the Investors & Media section of the companys website at https://ir.gritstonebio.com/investors/events .
  • Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
  • Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.

Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern

Retrieved on: 
Tuesday, August 17, 2021
Vaccine, Epidemic, National Institute of Allergy and Infectious Diseases, University, NIAID, COVID, Program, SAGE, Faculty, Severe acute respiratory syndrome coronavirus 2, U.S. Securities and Exchange Commission, Infection, Immune system, GLOBE, CEPI, Gilead Sciences, Antigen, COVAX, La Jolla Institute for Immunology, CORAL, University of the Witwatersrand, Outline of health sciences, Cell, HIV, National, Bill & Melinda Gates Foundation, Immunodeficiency, Epitope, Coalition, Clinical trial, RNA transfection, Immunology, SAM, McMaster Faculty of Health Sciences, Volunteering, Coalition for Epidemic Preparedness Innovations, Patient, Solution, CEO, Bill, NIH, Neoplasm, SLATE, COVID-19, National Institute, Convalescence, Security (finance), Pharmaceutical industry

With this unique antigenic breadth, our CORAL vaccine may offer protection against emerging spike variants of SARS-CoV-2 that appear challenging for first generation vaccines, said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone.

Key Points: 
  • With this unique antigenic breadth, our CORAL vaccine may offer protection against emerging spike variants of SARS-CoV-2 that appear challenging for first generation vaccines, said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone.
  • Under the terms of the agreement, CEPI will fund a multi-arm Phase 1 study evaluating the CORAL programs SAM vaccine in nave, convalescent, and HIV+ patients.
  • Gritstones CORAL program is a second-generation SARS-CoV-2 vaccine platform delivering spike and additional SARS-CoV-2 T cell epitopes, offering the potential for deep, broad, and durable protection against SARS-CoV-2 variants.
  • Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.

EDCTP and CEPI Funding Moves IAVI's Lassa fever Vaccine Candidate Into Advanced Clinical Development

Retrieved on: 
Tuesday, June 15, 2021
AIDS, Health, Other Health, General Health, Clinical trials, Research, Science, Medical specialties, Clinical medicine, Medicine, Ebola, Breakthrough therapy, Vaccines, West African Ebola virus epidemic, Lassa fever, Ebola vaccine, rVSV-ZEBOV vaccine, Vaccine, Lassa, Lassa Fever, EDCTP, CEPI, IAVI, LASSA FEVER, EDCTP, CEPI, IAVI

Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.

Key Points: 
  • Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.
  • The joint award supports an international collaboration, called Lassa Fever Vaccine Efficacy and Prevention for West Africa (LEAP4WA), to conduct a Phase IIb clinical trial of IAVIs Lassa fever vaccine candidate among adults and children in Liberia, Nigeria, and Sierra Leone.
  • LEAP4WA builds on an existing partnership with CEPI that supports IAVI and a global consortium of partners to conduct Phase I and II clinical trials of IAVIs Lassa fever vaccine candidate.
  • We are excited to apply the recombinant VSV technology, used in the previously licensed Ebola vaccine called ERVEBO, for the development of a much-needed Lassa fever vaccine.

CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates Against COVID-19 Variants

Retrieved on: 
Wednesday, March 10, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Vaccination, Vaccine, Virology, Medical research, Medicine, Health sciences, Coalition for Epidemic Preparedness Innovations, CEPI, VBI Vaccines Inc, COVAX

This preclinical expansion is intended to develop clinic-ready vaccine candidates capable of addressing emerging variants.

Key Points: 
  • This preclinical expansion is intended to develop clinic-ready vaccine candidates capable of addressing emerging variants.
  • CEPI is investing in the development of vaccines against COVID-19 variants to help the world to stay one step ahead of the virus.
  • VBI and CEPI expect to initiate Phase 1 studies of VBI-2905 the first eVLP-based vaccine candidate in the CEPI portfolio - mid-year 2021.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

Retrieved on: 
Friday, December 4, 2020
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Health sciences, Vaccination, Medicine, Medical research, Vaccines, Virology, COVID-19 vaccine, Reactogenicity, Adjuvant, Vaccine, H5N1 clinical trials, COVID-19 S-Trimer Vaccine, Trimer-Tag© Technology, Clover Biopharmaceuticals, GSK, Dynavax, CEPI

The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels.

Key Points: 
  • The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels.
  • Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant.
  • Thus, the ability of Clovers COVID-19 vaccine candidates to be stored in standard refrigeration temperatures makes them suitable for broad global distribution based on current results.
  • Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines.

Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine

Retrieved on: 
Tuesday, October 29, 2019
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Medical specialties, Infectious diseases, Medicine, Coalition for Epidemic Preparedness Innovations, Epidemics, Tropical diseases, Biological weapons, Zoonoses, RTT, Lassa fever, Lassa, Vaccine, Lassa Fever, CEPI, Themis

Themis Bioscience and CEPI the Coalition for Epidemic Preparedness Innovations announced today the first administration to healthy volunteers in a Phase 1 clinical trial with Themis vaccine candidate against Lassa fever.

Key Points: 
  • Themis Bioscience and CEPI the Coalition for Epidemic Preparedness Innovations announced today the first administration to healthy volunteers in a Phase 1 clinical trial with Themis vaccine candidate against Lassa fever.
  • The MV-LASV Lassa fever vaccine candidate, is based on Themis proprietary measles vector platform and exclusively-licensed discoveries made at Institut Pasteur.
  • Our partnership with CEPI for Lassa fever further validates our capabilities and represents our combined commitment to tackle diseases that remain a public health threat globally.
  • Dr. Melanie Saville, Director of Vaccine Development at CEPI added: Themis was the first company CEPI partnered with to develop a vaccine against Lassa fever and MERS, two of our priority pathogens.